Cargando…

Pre-clinical Evaluation of a Cyanine-Based SPECT Probe for Multimodal Tumor Necrosis Imaging

PURPOSE: Recently we showed that a number of carboxylated near-infrared fluorescent (NIRF) cyanine dyes possess strong necrosis avid properties in vitro as well as in different mouse models of spontaneous and therapy-induced tumor necrosis, indicating their potential use for cancer diagnostic- and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Stammes, Marieke A., Knol-Blankevoort, Vicky T., Cruz, Luis J., Feitsma, Hans R. I. J., Mezzanotte, Laura, Cordfunke, Robert A., Sinisi, Riccardo, Dubikovskaya, Elena A., Maeda, Azusa, DaCosta, Ralph S., Bierau, Katja, Chan, Alan, Kaijzel, Eric L., Snoeks, Thomas J. A., van Beek, Ermond R., Löwik, Clemens W. G. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093207/
https://www.ncbi.nlm.nih.gov/pubmed/27277828
http://dx.doi.org/10.1007/s11307-016-0972-7
_version_ 1782464870499745792
author Stammes, Marieke A.
Knol-Blankevoort, Vicky T.
Cruz, Luis J.
Feitsma, Hans R. I. J.
Mezzanotte, Laura
Cordfunke, Robert A.
Sinisi, Riccardo
Dubikovskaya, Elena A.
Maeda, Azusa
DaCosta, Ralph S.
Bierau, Katja
Chan, Alan
Kaijzel, Eric L.
Snoeks, Thomas J. A.
van Beek, Ermond R.
Löwik, Clemens W. G. M.
author_facet Stammes, Marieke A.
Knol-Blankevoort, Vicky T.
Cruz, Luis J.
Feitsma, Hans R. I. J.
Mezzanotte, Laura
Cordfunke, Robert A.
Sinisi, Riccardo
Dubikovskaya, Elena A.
Maeda, Azusa
DaCosta, Ralph S.
Bierau, Katja
Chan, Alan
Kaijzel, Eric L.
Snoeks, Thomas J. A.
van Beek, Ermond R.
Löwik, Clemens W. G. M.
author_sort Stammes, Marieke A.
collection PubMed
description PURPOSE: Recently we showed that a number of carboxylated near-infrared fluorescent (NIRF) cyanine dyes possess strong necrosis avid properties in vitro as well as in different mouse models of spontaneous and therapy-induced tumor necrosis, indicating their potential use for cancer diagnostic- and prognostic purposes. In the previous study, the detection of the cyanines was achieved by whole body optical imaging, a technique that, due to the limited penetration of near-infrared light, is not suitable for investigations deeper than 1 cm within the human body. Therefore, in order to facilitate clinical translation, the purpose of the present study was to generate a necrosis avid cyanine-based NIRF probe that could also be used for single photon emission computed tomography (SPECT). For this, the necrosis avid NIRF cyanine HQ4 was radiolabeled with (111)indium, via the chelate diethylene triamine pentaacetic acid (DTPA). PROCEDURES: The necrosis avid properties of the radiotracer [(111)In]DTPA-HQ4 were examined in vitro and in vivo in different breast tumor models in mice using SPECT and optical imaging. Moreover, biodistribution studies were performed to examine the pharmacokinetics of the probe in vivo. RESULTS: Using optical imaging and radioactivity measurements, in vitro, we showed selective accumulation of [(111)In]DTPA-HQ4 in dead cells. Using SPECT and in biodistribution studies, the necrosis avidity of the radiotracer was confirmed in a 4T1 mouse breast cancer model of spontaneous tumor necrosis and in a MCF-7 human breast cancer model of chemotherapy-induced tumor necrosis. CONCLUSIONS: The radiotracer [(111)In]DTPA-HQ4 possessed strong and selective necrosis avidity in vitro and in various mouse models of tumor necrosis in vivo, indicating its potential to be clinically applied for diagnostic purposes and to monitor anti-cancer treatment efficacy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11307-016-0972-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5093207
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-50932072016-11-17 Pre-clinical Evaluation of a Cyanine-Based SPECT Probe for Multimodal Tumor Necrosis Imaging Stammes, Marieke A. Knol-Blankevoort, Vicky T. Cruz, Luis J. Feitsma, Hans R. I. J. Mezzanotte, Laura Cordfunke, Robert A. Sinisi, Riccardo Dubikovskaya, Elena A. Maeda, Azusa DaCosta, Ralph S. Bierau, Katja Chan, Alan Kaijzel, Eric L. Snoeks, Thomas J. A. van Beek, Ermond R. Löwik, Clemens W. G. M. Mol Imaging Biol Research Article PURPOSE: Recently we showed that a number of carboxylated near-infrared fluorescent (NIRF) cyanine dyes possess strong necrosis avid properties in vitro as well as in different mouse models of spontaneous and therapy-induced tumor necrosis, indicating their potential use for cancer diagnostic- and prognostic purposes. In the previous study, the detection of the cyanines was achieved by whole body optical imaging, a technique that, due to the limited penetration of near-infrared light, is not suitable for investigations deeper than 1 cm within the human body. Therefore, in order to facilitate clinical translation, the purpose of the present study was to generate a necrosis avid cyanine-based NIRF probe that could also be used for single photon emission computed tomography (SPECT). For this, the necrosis avid NIRF cyanine HQ4 was radiolabeled with (111)indium, via the chelate diethylene triamine pentaacetic acid (DTPA). PROCEDURES: The necrosis avid properties of the radiotracer [(111)In]DTPA-HQ4 were examined in vitro and in vivo in different breast tumor models in mice using SPECT and optical imaging. Moreover, biodistribution studies were performed to examine the pharmacokinetics of the probe in vivo. RESULTS: Using optical imaging and radioactivity measurements, in vitro, we showed selective accumulation of [(111)In]DTPA-HQ4 in dead cells. Using SPECT and in biodistribution studies, the necrosis avidity of the radiotracer was confirmed in a 4T1 mouse breast cancer model of spontaneous tumor necrosis and in a MCF-7 human breast cancer model of chemotherapy-induced tumor necrosis. CONCLUSIONS: The radiotracer [(111)In]DTPA-HQ4 possessed strong and selective necrosis avidity in vitro and in various mouse models of tumor necrosis in vivo, indicating its potential to be clinically applied for diagnostic purposes and to monitor anti-cancer treatment efficacy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11307-016-0972-7) contains supplementary material, which is available to authorized users. Springer US 2016-06-08 2016 /pmc/articles/PMC5093207/ /pubmed/27277828 http://dx.doi.org/10.1007/s11307-016-0972-7 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research Article
Stammes, Marieke A.
Knol-Blankevoort, Vicky T.
Cruz, Luis J.
Feitsma, Hans R. I. J.
Mezzanotte, Laura
Cordfunke, Robert A.
Sinisi, Riccardo
Dubikovskaya, Elena A.
Maeda, Azusa
DaCosta, Ralph S.
Bierau, Katja
Chan, Alan
Kaijzel, Eric L.
Snoeks, Thomas J. A.
van Beek, Ermond R.
Löwik, Clemens W. G. M.
Pre-clinical Evaluation of a Cyanine-Based SPECT Probe for Multimodal Tumor Necrosis Imaging
title Pre-clinical Evaluation of a Cyanine-Based SPECT Probe for Multimodal Tumor Necrosis Imaging
title_full Pre-clinical Evaluation of a Cyanine-Based SPECT Probe for Multimodal Tumor Necrosis Imaging
title_fullStr Pre-clinical Evaluation of a Cyanine-Based SPECT Probe for Multimodal Tumor Necrosis Imaging
title_full_unstemmed Pre-clinical Evaluation of a Cyanine-Based SPECT Probe for Multimodal Tumor Necrosis Imaging
title_short Pre-clinical Evaluation of a Cyanine-Based SPECT Probe for Multimodal Tumor Necrosis Imaging
title_sort pre-clinical evaluation of a cyanine-based spect probe for multimodal tumor necrosis imaging
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093207/
https://www.ncbi.nlm.nih.gov/pubmed/27277828
http://dx.doi.org/10.1007/s11307-016-0972-7
work_keys_str_mv AT stammesmariekea preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging
AT knolblankevoortvickyt preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging
AT cruzluisj preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging
AT feitsmahansrij preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging
AT mezzanottelaura preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging
AT cordfunkeroberta preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging
AT sinisiriccardo preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging
AT dubikovskayaelenaa preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging
AT maedaazusa preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging
AT dacostaralphs preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging
AT bieraukatja preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging
AT chanalan preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging
AT kaijzelericl preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging
AT snoeksthomasja preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging
AT vanbeekermondr preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging
AT lowikclemenswgm preclinicalevaluationofacyaninebasedspectprobeformultimodaltumornecrosisimaging